- Tirzepatide demonstrated substantial reductions in energy intake and appetite in non-diabetic adults with obesity.
- Functional MRI revealed modulation of brain responses to food cues by tirzepatide.
- Tirzepatide produced significant weight loss but was associated with gastrointestinal adverse effects.
- The drug showed superior efficacy in appetite control compared to liraglutide.
- The study strengthens confidence in the findings with an 89% completion rate and robust statistical methodology.
Source: Nature Medicine
